玉屏风联合枸地氯雷他定治疗慢性荨麻疹有效性和安全性的荟萃分析

doi:10.11669/cpj.2021.22.011

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1881 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的系统评价玉屏风联合枸地氯雷他定治疗慢性荨麻疹(chronic urticaria,CU)有效性和安全性。方法计算机检索The Cochrane Library、PubMed、Embase、中国知网(CNKI)、万方数据库(WangFang Data)和中国生物医学文献数据库(CBM),纳入评价玉屏风联合枸地氯雷他定治疗CU的随机对照试验(randomized controlled trial,RCT),检索时限从建库至2021年6月。由2名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用Revman 5.4软件进行Meta分析。结果共纳入19项RCT研究,包括1 919例患者,治疗组956例,对照组963例。Meta分析结果显示:有效性方面,玉屏风联合枸地氯雷他定治疗CU在总有效率[OR=4.17,95%CI(2.96,5.86),P<0.01]、痊愈率[OR=2.10,95%CI(1.71,2.58),P<0.01]、复发率[OR=0.18,95%CI(0.13,0.28),P<0.01]、免疫球蛋白E(immunoglobulin E,IgE)[MD=-28.99,(95%CI:-35.56～-22.41),P＜0.01]、皮肤病生活质量指数(drmatology life quality index,DLQI)[MD=-5.84,(95%CI:-6.30～-5.37),P＜0.01]、风团个数[MD=-5.09,(95%CI:-5.40～-4.78),P＜0.01]、风团数目评分[MD=-0.34,(95%CI:-0.37～-0.32),P＜0.01]、风团持续时间[MD=-3.45,(95%CI:-3.83～-3.08),P＜0.01]、风团发作频率[MD=-9.03(95%CI:-9.63～-8.43),P＜0.01]、临床症状积分[MD=-2.10(95%CI:-2.62～-1.57),P＜0.01]和白细胞介素-4(Interleukin-4,IL-4)[MD=-20.08,(95%CI:-27.41～-12.75),P＜0.01]方面均显著优于对照组,差异有统计学意义;不良反应方面,治疗组[OR=0.85,(95%CI:0.49～1.46),P=0.55＞0.05],差异无统计学意义。结论现有证据表明,玉屏风联合枸地氯雷他定治疗CU安全、有效,不宜复发,较单独使用枸地氯雷他定有明显优势。结果证据受纳入研究的数量和质量限制,上述结论有待更多高质量研究予以验证。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	郑子恢
	潘慧杰
	张亚同
	张碧华
	李文英
	张白歌
	马琳
	金鹏飞

关键词 ：玉屏风, 枸地氯雷他定, 慢性荨麻疹, Meta分析, 随机对照试验

Abstract：OBJECTIVE To systematically evaluate the efficacy and safety of Yupingfeng with desloratadine citrate disodium in the chronic urticaria(CU). METHODS The Cochrane Library, PubMed, Embase, CNKI, Wanfang Data, and CBM were retrieved until Jun 2021. Two researchers independently screened the literature, extracted the data, and evaluated the risk of bias in the included study, the Revman 5.4 software was used for Meta analysis. RESULTS A total of 19 randamized controlled trials(RCT) were included in the analysis, including 1 919 patients, 956 in the experimental group and 963 in the control group. Meta-analysis results showed that: in terms of effectiveness, the total effective rate of Yupingfeng combined with desloratadine citrate disodium in the chronic urticaria [OR=4.17, 95%CI(2.96,5.86), P<0.01], cure rate [OR=2.12, 95%CI(1.59,2.82), P<0.01], recurrence rate[OR=0.18, 95%CI(0.13,0.28), P<0.01], immunoglobulin E(IgE) [MD=-28.99,(95%CI:-35.56--22.41), P＜0.01], drmatology life quality index(DLQI)[MD=-5.84,(95%CI:-6.30--5.37), P＜0.01], wind group number [MD=-5.09,(95%CI:-5.40--4.78),P＜0.01], score the number of wind clusters [MD=-0.34,(95%CI:-0.37--0.32), P＜0.01], duration of wind cluster [MD=-3.45,(95%CI:-3.83--3.08), P＜0.01], frequency of wind cluster occurrence [MD=-9.03(95%CI:-9.63--8.43), P＜0.01], clinical symptom score [MD=-2.10(95%CI:-2.62--1.57), P＜0.01] and interleukin-4(IL-4) [MD=-20.08,(95%CI:-27.41--12.75), P＜0.01][MD=-5.58, (95%CI:-6.38--4.78),P＜0.01] were significantly better than the control group, and the difference was statistically significant . In terms of adverse reactions, there was no statistical significance in the study group [OR=0.85,(95%CI:0.49-1.46),P=0.55＞0.05]. CONCLUSION The existing evidence shows that Yupingfeng with desloratadine citrate disodium is safe and effective in the treatment of chronic urticaria, and has obvious advantages over desloratadine citrate disodium alone. The evidence was limited by the quantity and quality of the included studies, and the above conclusions need to be verified by more high-quality studies.

Key words： Yupingfeng desloratadine citrate disodium chronic urticaria Meta-analysis randomized controlled trial

收稿日期: 2021-05-17

PACS:

R95

基金资助:国家自然科学基金项目资助(81303216);北京市自然科学基金项目资助(7113164)

通讯作者: *金鹏飞,男,主任药师研究方向:医院药学,药物分析 Tel:(010)85133620

作者简介: 郑子恢,男,主管药师研究方向:医院药学,循证药学; 潘慧杰,女,主管技师研究方向:临床检验,循证医学。郑子恢与潘慧杰为共同第一作者

引用本文:

郑子恢, 潘慧杰, 张亚同, 张碧华, 李文英, 张白歌, 马琳, 金鹏飞. 玉屏风联合枸地氯雷他定治疗慢性荨麻疹有效性和安全性的荟萃分析[J]. 中国药学杂志, 2021, 56(22): 1844-1854. ZHENG Zi-hui, PAN Hui-jie, ZHENG Ya-tong, ZHANG Bi-hua, LI Wen-ying, ZHANG Bai-ge, MA Lin, JIN Peng-fei. Systematic Evaluation of the Efficacy and Safety of Yupingfeng Combined with Desloratadine Citrate Disodium in the Chronic Urticaria. Chinese Pharmaceutical Journal, 2021, 56(22): 1844-1854.

链接本文:

http://journal11.magtechjournal.com/Jwk_zgyxzz/CN/10.11669/cpj.2021.22.011 或 http://journal11.magtechjournal.com/Jwk_zgyxzz/CN/Y2021/V56/I22/1844

[1]	ZUBERBIER T, ABERER W, ASERO R, et al. The EAACI/GA 2 LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria[J]. Allergy, 2018, 73(7):1393-1414.
[2]	BERNSTEIN J A, LANG D M, KHAN D A, et al. The diagnosis and management of acute and chronic urticaria:2014 update[J]. Allergy Clin Immunol, 2014, 133(5):1270-1277.
[3]	GUO C, SALTOUN C.Urticaria and angioedema[J]. Allergy Asthma Proc.2019, 40(6):437-440.
[4]	PONS-GUIRAUD A, NEKAM K, LAHOVSKY J, et al. Emedastine difumarate versus loratadine in chronic idiopathic urticarial:a randomized, double-blind, controlled European muhicentre clinical trial[J]. Eur J Dermatol , 2015, 16(6):649-654.
[5]	KANANI A, BETSCHEL S D, WARRINGTON R. Urticaria and angioedema[J]. Allergy Asthma Clin Immunol, 2018, 14(Suppl 2):59.
[6]	HAO F, LU Q J, SONG Z Q. Guidelines for diagnosis and treatment of urticaria in China(2014) [J]. Chin J Dermatol(中华皮肤科杂志), 2014, 47(7):514-516.
[7]	Centre for Urticaria Research, Chinese Society of Dermatology. Guidelines for diagnosis and treatment of urticaria in China(2018) [J]. Chin J Dermatol(中华皮肤科杂志), 2019, 52(1):1-5.
[8]	ASERO R, PINTER E, MARRA A M, et al. Current challenges and controversies in the management of chronic spontaneous urticaria[J]. Expert Rev Clin Immunol, 2015, 11(10):1073-1082.
[9]	COOKE A, BULKHI A, CASALE T B. Role of biologics in intractable urticaria[J]. Biologics, 2015, 13(9):25-33.
[10]	Zuberbier T, Maurer M. Omalizumab for the treatment of chronic urticaria[J]. Expert Rev Clin Immunol, 2015, 11(2):171-180.
[11]	Asero R, Tedeschi A. Usefulness of a short course of oral prednisone in antihistamine resistant chronic urticaria:a retrospective analysis[J]. J Investig Allergol Clin Immunol, 2010, 20(5):386-390.
[12]	HIRAGUN M, HIRAGUN T, MIHARA S, et al. Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine[J]. Allergy, 2013, 68(2):229-235.
[13]	ZUBERBIER T, ABERER W, ASERO R, et al. Dermatology Section of the European Academy of Allergy and Clinical Immunology; Golbal Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria[J]. Allergy, 2014, 69(7):1-29.
[14]	RICARDO C P, CRIADO R F J, MARUTA C W, et al. Chronic urticaria in adults:state of the art in the new millennium[J]. An Bras Dermatol, 2015, 90(1):74-89.
[15]	MAO Y P, TAN G Z, ZHANG C Y, et al. Clinical Study on the Efficacy and Safety of Citrus Medica Ground Ioratadine Tablets in the Treatment of Chronic Idiopathic Urticaria [J]. China J Dermatovenereol (中国皮肤性病学杂志), 2014, 28(9):974-976.
[16]	ZHANG Q W, LIANG B H, LI R X, et al. Research progress on pathogenesis and treatment of chronic spontaneous urticaria[J]. J Diagn Ther Dermvenereol (皮肤性病诊疗学杂志), 2015, 22(4):332-335.
[17]	LI S D. The summary of the clinical efficacy of the combination of jade screen powder and angelica cold-extremities decoction on treating cold urticaria of 66patients [J]. Clin J China Med (中医临床研究), 2014, 6(9):67-68.
[18]	Dermatology Branch of China Association of Traditional Chinese Medicine. Addiction rash (urticaria) Chinese medicine treatment expert consensus [J]. China J Dermatovenerol Integr Radit Western Med(中国中西医结合皮肤性病学杂志), 2017, 16(3):274-275.
[19]	Ministry of Health of the People's Republic of China. Guiding Principles for Clinical Research of New Chinese Medicine(中药新药临床研究指导原则第三辑) [M]. Beijing: Chinese Medicine Science and technology Press, 1997:86-89.
[20]	The Cochrane Collaboration.Cochrane handbook for systematic reviews of interventions version.1.0[EB/OL]. [2019-04-26]. 2011-03, http:∥www.cochrane.org/.
[21]	CUMPSTON M, LI T, PAGE M J, et al. Updated guidance for trusted systematic reviews:a new edition of the Cochrane Handbook for Systematic Reviews of Interventions[J]. Cochrane Database Syst Rev, 2019, 10:ED000142.
[22]	CHEN M. Effect of Yupingfeng Capsule Combined with Chloratadine citrate Tablets on Chronic Urticaria and Its Effect on Serum Total IgE and Inflammatory Factor Levels [J]. Mod J Integr Tradit Chin West Med (现代中西医结合杂志), 2017, 26(33):3740-3742.
[23]	FAN N, LU J, MA J, et al. Clinical effect of Yupingfeng granule in the adjuvant treatment of 36 cases of chronic urticaria and its impact on Th1/Th2 immune balance[J]. Clin Res Pract (临床医学研究与实践), 2019, 4(22):147-148.
[24]	FU H D, ZHANG Z, XU M. Efficacy observation of Yupingfeng granule in adjuvant treatment of chronic urticaria with blood deficiency and wind dryness [J]. J New Chin Med(新中医), 2015, 47(7):174-176.
[25]	HU L H. Clinical research on the clinical effect of urticaria in Yupingfeng granules combine with desloratadine [J]. Shaanxi J Tradit Chin Med(陕西中医), 2017, 38(6):759-761.
[26]	LI Y L, ZHANG J F. The Clinical Effect of Desloratadine Citrate Disosium Tablets Combined with Yupingfeng Granules in the Treatment of Chronic Urticaria [J]. Med Innov China(中国医学创新), 2020, 17(17):68-71.
[27]	LI Y Y. Clinical 0bservation on Treatment of Chronic Urticaria with Yupingfeng San Combined with Desalination[J]. Guide China Med(中国医药指南), 2020, 18(26):131-132.
[28]	LIANG Q S. Therapeutic Observation of the Effect of Combining Therapy of Desloratadine Citrate Disodium Capsules and Yupengfeng on Chronic Idiopathic Urticaria[J]. Chin J Clin Ration Drug Use(临床合理用药杂志), 2012, 5(21):59-60.
[29]	QIN F, QUE H X, CUI C J. Clinical observation of yupingfeng capsule combined with citrate loratadine tablet in the treatment of chronic urticaria [J]. J Med Theory Pract (医学理论与实践), 2016, 29(5):639-640.
[30]	REN Y L, CHAO L Q. Effect of Yupingfeng Granule on Clinical Symptoms and Inflammatory Factors in Patients with Chronic Urticaria [J]. Chron Pathematol J (慢性病学杂志), 2019, 20(1):148-150.
[31]	SU Y H, SHI L L, SHI X, et al. Clinical observation of 100 cases of chronic urticaria treated by Yupingfeng granule combined with citrate loratadine [J]. Chin J Dermatol (中华皮肤科杂志), 2018, 51(1):55-57.
[32]	TIAN J, HUANG S B. Therapeutic observation of the effect of combining therapy of desloratadine citrate disodium capsules and yupengfeng on chronic urticaria and effects on serum levels of ige [J]. Chin J Med(中国医刊), 2015,60(3):79-81.
[33]	WANG B G, ZHANG S W.Treatment of chronic urticaria by adding and subtracting Yupingfeng powder combined with chloratadine citrate Clinical effect analysis [J]. Chin J Mod Drug Appl (中国现代药物应用), 2019, 13(16):147-148.
[34]	WANG J, YANG G S. Clinical study on treatment of chronic urticaria by citrate loratadine tablet combined with yupingfeng capsule [J]. J Anhui Univ Chin Med (安徽中医药大学学报), 2021, 40(1):34-37.
[35]	WANG Q.Effect analysis of yupingfeng capsule combined with citrate loratadine tablet on chronic urticaria [J]. Jilin Med J (吉林医学), 2020, 41(3):618-619.
[36]	WANG T. Observation on the effect of dioratadine combined with Yupingfeng granules in sequential treatment of chronic urticaria and its effect on VAS score [J]. Chin Commun Doct(中国社区医师), 2019, 35(30):117-119.
[37]	WANG Y P, CHEN W N, MA J, et al. Exploring the Clinical Effect and Effect of Yupingfeng Granule Combined with Sedative Ralliplatin in the Treatment of Chronic Urticaria [J]. World J Complex Med (世界复合医学), 2019, 5(9):120-122, 138.
[38]	WEI X, ZHANG H B. Clinical observation on 81 cases of chronic urticaria treated by citronidatadine tablet combined with yupingfeng capsule [J]. Chin J Dermatovenereol Integr Tradit West Med (中国中西医结合皮肤性病学杂志), 2013, 12(4):249-250.
[39]	XIA H. Clinical observation on the sequential treatment of chronic urticaria by diloratadine combined with Yupingfeng granules[J]. Chin J Dermatovenereol Integr Tradit West Med(中国中西医结合皮肤性病学杂志), 2018, 17(5):436-438.
[40]	ZHAO C H, JIN Y, QIAN X Y, et al. Efficacy observation of desloratadine citrate disodium combined with Yupingfeng Granule in the treatment of chronic urticaria [J]. Shanghai J Tradit Chin Med(上海中医药杂志), 2017, 51(9):74-77.
[41]	PING J D, ZHAO J W, SUN X X, et al. Research progress of blood markers related to chronic urticaria [J]. J Diagn Ther J Dermatol-Venereol(皮肤性病诊疗学杂志), 2018, 25(1):50-52.
[42]	ZHANG M H, DAI Q M, HU C Y, et al. Expressions of interleukin-9 and the transcription factor PU.1 in peripheral blood of patients with chronic urticaria and their significance [J]. Chin J Dermatol(中华皮肤科杂志), 2015, 48(2):108-111.
[43]	JIE Q, KODITHUWAKKU N D, YUAN X, et al. Anti-allergic and anti-inflammatory properties of a potent histamine H1 receptor antagonist, desloratadine citrate disodium injection, and its anti-inflammatory mechanism on EA.hy926 endothelial cells[J]. Eur J Pharmacol, 2015, 754:1-10.
[44]	NAAMAN S, SUSSMAN G. Chronic idiopathic urticaria:treatment with omalizumab[J]. Skin Ther Lett, 2014, 19(6):1-4.
[45]	AUYEUNG P, MITTAG D, HODGKIN P D, et al. Autoreactive T cells in chronic spontaneous urticaria target the IgE Fc receptor Iαsubunit[J]. J Allergy Clin Immunol, 2016, 138(3):761-768.
[46]	WANG S F, GAO X Q, XU Y N, et al. Elevated Plasma Level of Interferon-λ1 in Chronic Spontaneous Urticaria:Upregulated Expression in CD8+ and Epithelial Cells and Induction of Inflammatory Cell Accumulation[J]. Mediat Inflamm, 2016, 2016:5032051.
[47]	XING S Y. Efficacy analysis of yupingfeng powder combined with citrate loratadine in the treatment of chronic urticaria [J]. Guide China Med (中国医药指南), 2018, 16(23):179.
[48]	LI Q, HU J H, GAO B, et al. Advances on Immunoregulation Effect of Astragalus Polysaccharides [J]. Chin J Exp Tradit Med Form(中国实验方剂学杂志), 2017, 23(2):199-204.
[49]	WU X B, JIN S Y, LI S M, et al. Effect of Saposhnikoviae Radix Extract on PAR-2 Expression and Related Cytokine Secretion of Mast Cells[J]. Chin J Exp Tradit Med Form (中国实验方剂学杂志), 2016, 22(5):123-126.
[50]	HUANG L, LI L M, TANG L Y. Effect of decoction of Atractylodes atractylodes on immune function in mice [J]. Pharmacol Clin Chin Mater Med(中药药理与临床), 2012, 28(1):114-115.